Oral Therapies in Oncology: Cognitive Function and Compliance
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 129
- 试验地点
- 1
- 主要终点
- Assess the relationship between cognitive function at baseline oral anti-cancer treatment and adherence to treatment.
研究概览
简要总结
The investigators propose to evaluate the compliance of oral cancer therapies, particularly the possible link between this observance and cognitive function of patients at initiation of treatment. To our knowledge, this study will be among the first conducted on the issue in France and is an innovative approach in the management of cancer patients. The inclusion of cognitive dysfunction is part of a comprehensive approach to improving the quality of life and fully meets the objectives of both plans cancer, including those of the axis "Living during and after cancer" highlighted in the Cancer Plan
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age over 18 years,
- •Patients treated with a first prescription of exclusive oral therapy (chemotherapy and/or targeted therapy) as part of a cancer,
- •Patients who begin treatment with ZYTIGA ® (abiraterone acetate) are incluables,
- •Patients with asymptomatic brain metastases are incluables,
- •Lack of personality disorders and psychiatric illness scalable,
- •Knowledge of spoken and written French,
- •Having signed the informed consent of study participation.
排除标准
- •Pathology psychiatric
- •Refusal to participate,
- •Patient unable to respond to cognitive tests, - Documented use of drugs,
- •Heavy drinking, - Cancer primitive central nervous system, - Participation in a clinical trial.
结局指标
主要结局
Assess the relationship between cognitive function at baseline oral anti-cancer treatment and adherence to treatment.
时间窗: 8 months
次要结局
未报告次要终点
